Loading...

Laboratorios Farmaceuticos Rovi

BST:41L
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
41L
BST
€997M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Laboratorios Farmaceuticos Rovi, S.A. produces and sells pharmaceutical products in Spain and internationally. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
41L Share Price and Events
7 Day Returns
0%
BST:41L
3.6%
DE Pharmaceuticals
1.7%
DE Market
1 Year Returns
-
BST:41L
-28.3%
DE Pharmaceuticals
-20.1%
DE Market
41L Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Laboratorios Farmaceuticos Rovi (41L) 0% 0% 3.5% - - -
DE Pharmaceuticals 3.6% -3.9% -7.4% -28.3% -22% 10.9%
DE Market 1.7% -3.9% -10.2% -20.1% 1.7% 1.9%
1 Year Return vs Industry and Market
  • No trading data on 41L.
  • No trading data on 41L.
Price Volatility
41L
Industry
5yr Volatility vs Market

Value

 Is Laboratorios Farmaceuticos Rovi undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Laboratorios Farmaceuticos Rovi to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Laboratorios Farmaceuticos Rovi.

BST:41L Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:41L
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 9.5%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.58
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.582 (1 + (1- 25%) (3.96%))
0.599
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.54% + (0.8 * 9.46%)
8.11%

Discounted Cash Flow Calculation for BST:41L using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Laboratorios Farmaceuticos Rovi is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:41L DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (EUR, Millions) 27.42 37.68 55.37 67.00 71.10
Source Analyst x5 Analyst x6 Analyst x3 Analyst x1 Est @ 6.12%
Present Value
Discounted (@ 8.11%)
25.36 32.24 43.82 49.05 48.15
Present value of next 5 years cash flows €198.62
BST:41L DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= €71.10 × (1 + 0.54%) ÷ (8.11% – 0.54%)
€944.74
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= €944.74 ÷ (1 + 8.11%)5
€639.76
BST:41L Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= €198.62 + €639.76
€838.38
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €838.38 / 55.38
€12.57
BST:41L Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:41L represents 0.83056x of BME:ROVI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.83056x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 15.14 x 0.83056
€12.57
Value per share (EUR) From above. €12.57
Current discount Discount to share price of €14.95
= -1 x (€14.95 - €12.57) / €12.57
-18.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Laboratorios Farmaceuticos Rovi is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Laboratorios Farmaceuticos Rovi's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Laboratorios Farmaceuticos Rovi's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:41L PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in EUR €0.32
BME:ROVI Share Price ** BME (2018-10-08) in EUR €18
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 14.06x
Germany Market PE Ratio Median Figure of 416 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Laboratorios Farmaceuticos Rovi.

BST:41L PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:ROVI Share Price ÷ EPS (both in EUR)

= 18 ÷ 0.32

55.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorios Farmaceuticos Rovi is overvalued based on earnings compared to the DE Pharmaceuticals industry average.
  • Laboratorios Farmaceuticos Rovi is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Laboratorios Farmaceuticos Rovi's expected growth come at a high price?
Raw Data
BST:41L PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 55.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
39.6%per year
Germany Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 1.17x
Germany Market PEG Ratio Median Figure of 278 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

BST:41L PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 55.92x ÷ 39.6%

1.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorios Farmaceuticos Rovi is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Laboratorios Farmaceuticos Rovi's assets?
Raw Data
BST:41L PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in EUR €4.08
BME:ROVI Share Price * BME (2018-10-08) in EUR €18
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 1.79x
Germany Market PB Ratio Median Figure of 563 Publicly-Listed Companies 1.72x
BST:41L PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:ROVI Share Price ÷ Book Value per Share (both in EUR)

= 18 ÷ 4.08

4.41x

* Primary Listing of Laboratorios Farmaceuticos Rovi.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorios Farmaceuticos Rovi is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Laboratorios Farmaceuticos Rovi's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Laboratorios Farmaceuticos Rovi has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Laboratorios Farmaceuticos Rovi expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Laboratorios Farmaceuticos Rovi expected to grow at an attractive rate?
  • Laboratorios Farmaceuticos Rovi's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Laboratorios Farmaceuticos Rovi's earnings growth is expected to exceed the Germany market average.
  • Laboratorios Farmaceuticos Rovi's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:41L Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:41L Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 39.6%
BST:41L Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 10.6%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 10.4%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:41L Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:41L Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 459 1
2022-12-31 466 85 84 2
2021-12-31 437 57 59 4
2020-12-31 365 45 46 9
2019-12-31 329 20 24 10
2018-12-31 298 8 15 9
BST:41L Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-09-30 291 8 16
2018-06-30 283 16 9
2018-03-31 284 30 18
2017-12-31 276 18 17
2017-09-30 277 21 22
2017-06-30 275 25 24
2017-03-31 272 24 23
2016-12-31 265 46 26
2016-09-30 260 44 25
2016-06-30 254 38 24
2016-03-31 246 40 23
2015-12-31 246 29 20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Laboratorios Farmaceuticos Rovi's earnings are expected to grow significantly at over 20% yearly.
  • Laboratorios Farmaceuticos Rovi's revenue is expected to grow by 10.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:41L Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Laboratorios Farmaceuticos Rovi Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:41L Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 1.50 1.50 1.50 1.00
2021-12-31 1.05 1.17 0.83 3.00
2020-12-31 0.86 1.11 0.73 6.00
2019-12-31 0.46 0.52 0.41 7.00
2018-12-31 0.27 0.28 0.25 4.00
BST:41L Past Financials Data
Date (Data in EUR Millions) EPS *
2018-09-30 0.32
2018-06-30 0.18
2018-03-31
2017-12-31 0.35
2017-09-30
2017-06-30 0.48
2017-03-31
2016-12-31 0.53
2016-09-30
2016-06-30 0.49
2016-03-31
2015-12-31 0.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Laboratorios Farmaceuticos Rovi is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Laboratorios Farmaceuticos Rovi's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Laboratorios Farmaceuticos Rovi has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Laboratorios Farmaceuticos Rovi performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Laboratorios Farmaceuticos Rovi's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Laboratorios Farmaceuticos Rovi's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Laboratorios Farmaceuticos Rovi's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Laboratorios Farmaceuticos Rovi's 1-year earnings growth is negative, it can't be compared to the DE Pharmaceuticals industry average.
Earnings and Revenue History
Laboratorios Farmaceuticos Rovi's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Laboratorios Farmaceuticos Rovi Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:41L Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 291.13 15.87 88.65
2018-06-30 283.20 9.03 86.66
2018-03-31 283.96 17.71 85.25
2017-12-31 275.65 17.24 83.33
2017-09-30 277.12 21.59 80.77
2017-06-30 275.07 23.84 80.35
2017-03-31 271.96 23.06 79.36
2016-12-31 265.17 26.09 79.04
2016-09-30 259.82 24.81 84.03
2016-06-30 253.61 24.24 84.29
2016-03-31 245.91 22.76 84.59
2015-12-31 246.01 19.81 84.43
2015-09-30 242.40 20.76 53.28 -8.87
2015-06-30 243.00 22.73 78.12
2015-03-31 241.19 24.64 76.47
2014-12-31 238.05 24.12 75.45
2014-09-30 229.95 24.21 76.88 1.08
2014-06-30 224.28 24.15 77.40
2014-03-31 221.43 23.61 77.81
2013-12-31 217.59 23.02 76.10
2013-09-30 209.27 21.56 102.50 7.79
2013-06-30 206.66 20.39 75.75
2013-03-31 204.76 19.60 75.50
2012-12-31 201.92 19.51 75.03
2012-09-30 198.12 19.01 74.02
2012-06-30 193.70 18.21 73.26
2012-03-31 188.88 18.53 71.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Laboratorios Farmaceuticos Rovi has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Laboratorios Farmaceuticos Rovi used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Laboratorios Farmaceuticos Rovi's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Laboratorios Farmaceuticos Rovi's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Laboratorios Farmaceuticos Rovi has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Laboratorios Farmaceuticos Rovi's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Laboratorios Farmaceuticos Rovi's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Laboratorios Farmaceuticos Rovi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Laboratorios Farmaceuticos Rovi's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Laboratorios Farmaceuticos Rovi's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Laboratorios Farmaceuticos Rovi Company Filings, last reported 3 months ago.

BST:41L Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 201.10 39.52 17.47
2018-06-30 193.11 38.46 30.03
2018-03-31 198.63 40.42 38.97
2017-12-31 191.69 43.24 40.75
2017-09-30 191.44 47.10 44.17
2017-06-30 190.12 49.14 54.15
2017-03-31 190.02 51.30 47.66
2016-12-31 183.41 33.79 41.41
2016-09-30 179.01 37.63 40.72
2016-06-30 175.50 39.72 44.67
2016-03-31 173.98 41.44 39.93
2015-12-31 164.79 42.78 29.31
2015-09-30 162.23 44.15 25.58
2015-06-30 159.27 35.04 25.74
2015-03-31 165.14 35.94 27.86
2014-12-31 158.47 36.31 26.73
2014-09-30 154.49 37.29 28.24
2014-06-30 151.16 25.21 25.28
2014-03-31 149.97 30.23 12.87
2013-12-31 144.46 30.98 19.46
2013-09-30 140.22 31.53 17.07
2013-06-30 133.39 32.05 22.42
2013-03-31 132.48 38.09 22.19
2012-12-31 126.45 38.39 16.65
2012-09-30 123.57 38.52 21.62
2012-06-30 120.25 38.96 37.61
2012-03-31 119.11 43.93 43.52
  • Laboratorios Farmaceuticos Rovi's level of debt (19.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (22.5% vs 19.7% today).
  • Debt is well covered by operating cash flow (20.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 17.1x coverage).
X
Financial health checks
We assess Laboratorios Farmaceuticos Rovi's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Laboratorios Farmaceuticos Rovi has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Laboratorios Farmaceuticos Rovi's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.67%
Current annual income from Laboratorios Farmaceuticos Rovi dividends. Estimated to be 1.49% next year.
If you bought €2,000 of Laboratorios Farmaceuticos Rovi shares you are expected to receive €13 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Laboratorios Farmaceuticos Rovi's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.68%).
  • Laboratorios Farmaceuticos Rovi's dividend is below the markets top 25% of dividend payers in Germany (4.06%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:41L Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 31 Stocks 3.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:41L Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.53 1.00
2021-12-31 0.39 4.00
2020-12-31 0.27 7.00
2019-12-31 0.16 7.00
2018-12-31 0.10 8.00
BST:41L Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2018-02-20 0.121 0.727
2017-02-16 0.183 1.169
2016-02-24 0.139 1.042
2015-02-25 0.169 1.196
2014-02-27 0.161 1.688
2013-11-07 0.137 1.416
2013-07-31 0.137 1.709
2013-04-24 0.137 1.968
2013-02-20 0.137 2.052
2012-11-08 0.127 2.325
2012-07-26 0.127 2.443
2012-04-26 0.127 2.546
2012-02-23 0.127 2.602
2011-05-11 0.172 3.342
2011-02-24 0.172 3.398
2011-02-23 0.172 3.335
2010-07-29 0.141 2.872
2010-02-24 0.141 2.698
2010-01-04 0.141 1.975
2009-07-29 0.165 2.121
2009-02-26 0.165 3.133

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Laboratorios Farmaceuticos Rovi is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Laboratorios Farmaceuticos Rovi is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Laboratorios Farmaceuticos Rovi's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Laboratorios Farmaceuticos Rovi's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3.2x coverage).
X
Income/ dividend checks
We assess Laboratorios Farmaceuticos Rovi's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Laboratorios Farmaceuticos Rovi afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Laboratorios Farmaceuticos Rovi has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Laboratorios Farmaceuticos Rovi's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Juan Encina
COMPENSATION €524,000
TENURE AS CEO 2 years
CEO Bio

Mr. Juan López-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007. Mr. Encina has been with Laboratorios Farmaceuticos ROVI since 1994 and served as its General Director since October 2001. Mr. López-Belmonte Encina began his career carrying out diverse roles for various international pharmaceutical companies including the Nielzen Group in Spain, the Tyco Group in the United States and Boots Pharmaceutical in the United Kingdom. He has been Chairman of Board of Directors of Laboratorios Farmaceuticos ROVI for over 13 years. He has been a Director of Laboratorios Farmaceuticos ROVI, S.A. since July 27, 2007. He is a Member of the Board of Directors of the Madrid Chamber of Commerce, the Andalusia Technology Corporation Association, the Board of Directors and Executive Committee of Madrid Business Confederation and a member of the Management Board of ANEFP. Mr. López-Belmonte Encina Holds a Degree in Business and Economics from CEU San Pablo de Madrid, with an emphasis in auditing.

CEO Compensation
  • Juan's compensation has been consistent with company performance over the past year.
  • Juan's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Laboratorios Farmaceuticos Rovi management team in years:

10
Average Tenure
  • The average tenure for the Laboratorios Farmaceuticos Rovi management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Juan Encina

TITLE
CEO & Director
COMPENSATION
€524K
TENURE
2 yrs

Iván López-Belmonte Encina

TITLE
First Deputy Chairman & Corporate Development Manager
COMPENSATION
€406K

Javier López-Belmonte Encina

TITLE
Second Deputy Chairman & CFO
COMPENSATION
€404K
TENURE
18 yrs

Mercedes del Castillo Sánchez

TITLE
Legal Department Manager

Fernando Martínez Morales

TITLE
Director of Sales
TENURE
9.3 yrs

Rosario Perucha Pérez

TITLE
Marketing Manager

Francisco Angulo García

TITLE
Human Resources Manager

Gabriel Fernández

TITLE
Secretary

Javier Martínez González

TITLE
Director of Clinical Development

José Zapata Prieto

TITLE
Industrial Director
TENURE
10.8 yrs
Board of Directors Tenure

Average tenure of the Laboratorios Farmaceuticos Rovi board of directors in years:

3.6
Average Tenure
  • The tenure for the Laboratorios Farmaceuticos Rovi board of directors is about average.
Board of Directors

Juan López

TITLE
Chairman
COMPENSATION
€150K

Juan Encina

TITLE
CEO & Director
COMPENSATION
€524K
TENURE
11.5 yrs

Iván López-Belmonte Encina

TITLE
First Deputy Chairman & Corporate Development Manager
COMPENSATION
€406K
TENURE
3.2 yrs

Javier López-Belmonte Encina

TITLE
Second Deputy Chairman & CFO
COMPENSATION
€404K
TENURE
3.2 yrs

Enrique Castellón Leal

TITLE
Independent Director
COMPENSATION
€60K
TENURE
11.3 yrs

Miguel Corsini Freese

TITLE
Independent Director
COMPENSATION
€60K
AGE
73

José de Almansa Moreno-Barreda

TITLE
Independent Director
COMPENSATION
€60K
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Laboratorios Farmaceuticos Rovi's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Laboratorios Farmaceuticos Rovi has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Laboratorios Farmaceuticos Rovi, S.A. produces and sells pharmaceutical products in Spain and internationally. The company’s principal product is Bemiparin, a low molecular weight heparin. Its prescription products comprise Hibor to prevent thromboembolic disease; Hirobriz, Breezhale, and Ulunar Breezhaler for chronic obstructive pulmonary disease; Volutsa for the treatment of moderate to severe storage systems symptoms; and Medikinet and Medicebran for attention deficit and hyperactivity disorder. The company’s prescription products also include Exxiv for the symptoms of rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis; Neparvis for treatment of symptomatic chronic heart failure with reduced ejection; Absorcol, Vytorin, and Orvatez, and for hypercholesterolaemia; and Mysimba for the obesity treatment. In addition, it offers diagnostic products, such as SonoVue for use in ultrasound imaging; Iopamiro and Iomeron computed tomography and intervention; Multihance and Prohance for use in diagnostic magnetic resonance imaging; and EmpowerCTA, EmpowerMR, and CT Exprès contrast injection systems and compatible disposable material. Further, the company provides OTC products. Additionally, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Details
Name: Laboratorios Farmaceuticos Rovi, S.A.
41L
Exchange: BST
Founded: 1946
€996,802,704
55,377,928
Website: http://www.rovi.es
Address: Laboratorios Farmaceuticos Rovi, S.A.
Calle José Isbert, 2,
Madrid,
Madrid, 28223,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME ROVI Nominative Shares Bolsas y Mercados Espanoles ES EUR 18. Dec 2007
DB 41L Nominative Shares Deutsche Boerse AG DE EUR 18. Dec 2007
BST 41L Nominative Shares Boerse-Stuttgart DE EUR 18. Dec 2007
LSE 0ILL Nominative Shares London Stock Exchange GB EUR 18. Dec 2007
BATS-CHIXE ROVIE Nominative Shares BATS 'Chi-X Europe' GB EUR 18. Dec 2007
Number of employees
Current staff
Staff numbers
1,199
Laboratorios Farmaceuticos Rovi employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/05 22:04
End of day share price update: 2018/10/08 00:00
Last estimates confirmation: 2018/11/30
Last earnings filing: 2018/11/06
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.